Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 292

The DOI matches its Crossref record.

Antituberculosis Drug–induced Hepatotoxicity: The Role of Hepatitis C Virus and the Human Immunodeficiency Virus

UNGO, JAIME R., JONES, DENIS, ASHKIN, DAVID, HOLLENDER, ELENA S., BERNSTEIN, DAVID, ALBANESE, ANTHONY P., PITCHENIK, ARTHUR E.·1998·American Journal of Respiratory and Critical Care Medicine

Abstract

Until recently it was thought that age greater than 35 yr was the main risk factor for the development of drug-induced hepatitis (DIH) in patients receiving antituberculosis therapy. We conducted a study to determine whether infection with either the hepatitis C virus or the human immunodeficiency virus (HIV) were significant risk factors for the development of DIH in patients receiving antituberculosis therapy. Our study consisted of two parts. In the first part, 134 consecutive patients admitted for the treatment of tuberculosis (TB) were followed for the development of DIH. All of these patients were also screened for the presence of hepatitis C and HIV. In the second part of the study, those patients who were hepatitis C positive and who developed DIH on repeated reintroduction of the anti-TB drugs were offered a liver biopsy. If active inflammation, which may be suggestive of hepatitis C infection, was present on the biopsy specimen, treatment with alpha-interferon was begun and the anti-TB drugs were subsequently reintroduced. During the 18 mo of the study, 22 patients developed DIH. The relative risk of developing DIH if the patient was hepatitis C or HIV positive was fivefold and fourfold, respectively (p < 0.05). If a patient was coinfected with both hepatitis C and HIV the relative risk of developing DIH was increased 14.4-fold (p < 0.002). In the treatment part, four patients were treated with alpha-interferon, and all were able to undergo the reintroduction of anti-TB therapy without reoccurrence of DIH. Infection with hepatitis C and HIV are independent and additive risk factors for the development of DIH during TB therapy. The treatment of hepatitis C with alpha-interferon may allow the reintroduction of anti-TB agents in those who previously developed DIH when exposed to these drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/ajrccm.157.6.9711039

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 292

Metadata

Authors
UNGO, J. R., JONES, D., ASHKIN, D., HOLLENDER, E. S., BERNSTEIN, D., ALBANESE, A. P., & PITCHENIK, A. E.
Venue
American Journal of Respiratory and Critical Care Medicine
Published
1998-06-01
Volume
157
Issue
6
Pages
1871-1876
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W2157712198
Cited by
292
References
0
FWCI
6.38
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antituberculosis Drug–induced Hepatotoxicity: The Role of Hepatitis C Virus and the Human Immunodeficiency Virus. https://app.cochat.ai/papers/10.1164/ajrccm.157.6.9711039
The paper
UNGO, J. R., JONES, D., ASHKIN, D., HOLLENDER, E. S., BERNSTEIN, D., ALBANESE, A. P., & PITCHENIK, A. E. (1998). Antituberculosis Drug–induced Hepatotoxicity: The Role of Hepatitis C Virus and the Human Immunodeficiency Virus. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/ajrccm.157.6.9711039

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.